Febrile neutropenia in paediatric oncology
- PMID: 32336983
- PMCID: PMC7172100
- DOI: 10.1016/j.paed.2019.12.002
Febrile neutropenia in paediatric oncology
Abstract
Febrile neutropenia (FN) is a common and dangerous consequence of myelosuppressive chemotherapy but can occur as part of the disease processes. Bacterial bloodstream infection is the most commonly diagnosed cause of febrile neutropenia, with Gram-positive organisms most frequently isolated. However, Gram-negative organisms are becoming more prevalent, with a worrying trend towards resistant organisms. When FN is prolonged, lasting for more than 5 days, there is an increased risk of invasive fungal infections. Prompt recognition, diagnosis and initiation of treatment with broad-spectrum antibiotics are essential to avoid complications and prevent rapid progression to sepsis and possible death. This short article summarises the definition, causes, pathogenesis, applied physiology and management of FN in children.
Keywords: bacterial infection; bloodstream infection; chemotherapy febrile neutropenia; fungal infection; paediatric oncology.
© 2019 Elsevier Ltd. All rights reserved.
References
-
- Alexander S.W., Wade K.C., Hibberd P.L., Parsons S.K. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol. 2002;24:38–42. - PubMed
-
- Barton C.D., Waugh L.K., Nielsen M.J., Paulus S. Febrile neutropenia in children treated for malignancy. J Infect. 2015;71(suppl 1):S27–S35. - PubMed
-
- Bow E., Wingard J. 2019. Overview of neutropenic fever syndromes – UpToDate.https://ezproxy-prd.bodleian.ox.ac.uk:5093/contents/overview-of-neutrope... Available from:
-
- Klastersky J., de Naurois J., Rolston K. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):v111–v118. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous